872496-91-8

Basic information

• Product Name: (tert-butoxycarbonyl)-((4-(dimethyliminio)pyridin-1(4H)-yl)sulfonyl)amide
• CAS NO: 872496-91-8
• Molecular Weight: 301.367
• Mol File: 872496-91-8.mol

Chemical Properties

• CAS DataBase Reference: (tert-butoxycarbonyl)-((4-(dimethyliminio)pyridin-1(4H)-yl)sulfonyl)amide(CAS DataBase Reference)
• NIST Chemistry Reference: (tert-butoxycarbonyl)-((4-(dimethyliminio)pyridin-1(4H)-yl)sulfonyl)amide(872496-91-8)
• EPA Substance Registry System: (tert-butoxycarbonyl)-((4-(dimethyliminio)pyridin-1(4H)-yl)sulfonyl)amide(872496-91-8)

Safety Data

• Hazardous Substances Data: 872496-91-8(Hazardous Substances Data)

Upstream product

• 1122-58-3 dmap 
• 147000-89-3 N-tert-butyloxycarbonylsulfamoyl chloride 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 182925-52-6 C₁₇H₃₂N₂O₄S 
• 917882-55-4 tert-butyl [benzyl(methyl)sulfamoyl]carbamate 
• 1188932-00-4 tert-butyl-N-((R)-4-((1R,3aS,7aR,E)-4-(2-((3R,5R)-3,5-bis(tert-butyldimethylsilyloxy)cyclohexylidene)ethylidene)-7a-methyl-octahydro-7H-inden-1-yl)pentyl)sulfamoylcarbamate 
• 1188932-01-5 tert-butyl-N-((R)-5-((1R,3aS,7aR,E)-4-(2-((3R,5R)-3,5-bis-(tert-butyldimethylsilyloxy)cyclohexylidene)ethylidene)-7a-methyl-octahydro-7H-inden-1-yl)hexyl)sulfamoylcarbamate 
• 1188932-02-6 tert-butyl-N-((R)-6-((1R,3aS,7aR,E)-4-(2-((3R,5R)-3,5-bis(tert-butyldimethylsilyloxy)cyclohexylidene)ethylidene)-7a-methyloctahydro-7H-inden-1-yl)heptyl)sulfamoylcarbamate 
• 1312431-12-1 tert-butyl (N-((5-((6-phenylbenzo[d]thiazol-2-yl)methyl)-1,3,4-oxadiazol-2-yl)methyl)sulfamoyl)carbamate 
• 1258328-18-5 tert-butyl N-((1-benzylpiperidin-4-yl)methyl)sulfamoylcarbamate 
• 1231976-67-2 tert-butyl N-(3-nitrobenzylsulfamoyl)carbamate 
• 1402586-79-1 C₂₈H₃₃ClFN₅O₅S 

Relevant articles and documents

N-(tert-butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-ylsulfonyl]azanide: a new sulfamyolating agent. Structure and reactivity toward amines.

[structure: see text] Synthesis, structure, and reactivity toward amines of the new sulfamoylating reagent 2 are described. Compound 2 allowed sulfamoylation of amines under very mild conditions to give sulfamide derivatives in good yields.

QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

NOVEL ANTIBIOTIC COMPOUNDS

Novel antimicrobial inhibitors of Biotin Protein Ligase (BPL), which incorporate biotin, are described. The inhibitors have a structure that inhibit the essential metabolic enzyme BPL of pathogens and have been shown to be stable in whole blood and effect

ANTIBACTERIAL COMPOUNDS

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections.More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

Sulfonamide compound, preparation method and medical application thereof

The invention relates to a sulfonamide compound, a preparation method and medical application thereof. Specially, the invention relates to a compound shown as a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and application thereof as an agonist of farnesoid X receptor (FXR). The compound and the pharmaceutical composition containing the compound can be used for treating and/or preventing diseases associated with FXR activity, such as cholestatic disorders, diabetes and complications thereof, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatosis heptitis (NASH), obesity or metabolic syndromes (dyslipidemia, diabetes and combined disorders with abnormally high body mass indexes) and cardiovascular diseases. The definitions of each substituent in the general formula (I) are the same as those in the specification.

NOVEL NON-SYSTEMIC TGR5 AGONISTS

The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-sytemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

TRIAZOLE AGONISTS OF THE APJ RECEPTOR

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.

TETRACYCLIC CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

Discovery of novel FabF ligands inspired by platensimycin by integrating structure-based design with diversity-oriented synthetic accessibility

An approach for designing bioactive small molecules has been developed in which de novo structure-based ligand design (SBLD) was focused on regions of chemical space accessible using a diversity-oriented synthetic approach. The approach was exploited in the design and synthesis of a focused library of platensimycin analogues in which the complex bridged ring system was replaced with a series of alternative ring systems. The affinity of the resulting compounds for the C163Q mutant of FabF was determined using a WaterLOGSY competition binding assay. Several compounds had significantly improved affinity for the protein relative to a reference ligand. The integration of synthetic accessibility with ligand design enabled focus to be placed on synthetically-accessible regions of chemical space that were relevant to the target protein under investigation.

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)